REG - OptiBiotix Health - Commercial and scientific update

OptiBiotix HealthAnnouncement

20/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220720:nRST0234Ta&default-theme=true

RNS Number : 0234T  OptiBiotix Health PLC  20 July 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Commercial and scientific update

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare, provides
an update on recent scientific and commercial activities.

 

1.    Launch of WellBiome at IFT, USA: The Company has developed a new
formulation of WellBiome® as part of its health and wellness portfolio to
support healthy ageing. The product has several European and USA health claims
allowing on pack claims for heart health, bone health, cognitive health and
metabolic health. The formulation is protected by a portfolio of trademarks
and patents and was soft launched at IFT in Chicago, USA. The launch of
WellBiome® is part of a strategy of extending the Company's product portfolio
into other areas of healthcare.

 

2.    Clinical Study with University of Hull: The Company is conducting a
human intervention study with The University of Hull investigating the impact
of WellBiome® on reducing post operative complications and hospital stay. The
study is funded by the University of Hull with an intended start date either
in Q4 2022 or Q1 2023, subject to NHS ethics approval. There is growing
interest in the potential of prebiotics in post operative care as a means of
reducing pain, surgical complications, and the length of hospital stay.
Whilst exploratory, if successful, this study could open up opportunities for
WellBiome® in healthcare.

 

3.    LeanBiome® Certified as an Informed Ingredient for Sports: The
Company is pleased to announce that it has received approval for LeanBiome®
as an Informed Ingredient (see
 https://ingredient.wetestyoutrust.com/ingredient-search/optibiotix/leanbiome
(https://ingredient.wetestyoutrust.com/ingredient-search/optibiotix/leanbiome)
). This is an industry certification which demonstrates that LeanBiome® has
been through rigorous independent testing by an authorised body to confirm
that it is free from substances that are banned in sport. The risk of
contamination with low levels of substances prohibited by the World
Anti-Doping Agency (WADA) is a serious issue in sport. Certification of
LeanBiome® as an informed ingredient is an important step in attracting major
sports nutrition companies to incorporate LeanBiome® in their sports
nutrition products.

 

 

4.    SweetBiotix® Publication: The Company is pleased to announce the
publication of a study on the prebiotic activity and sweetness of one of its
SweetBiotix® products in a peer reviewed journal (see
https://pubs.acs.org/doi/10.1021/acs.jafc.2c01363
(https://pubs.acs.org/doi/10.1021/acs.jafc.2c01363) ). The study reports that
enzymatic synthesis of modified mogroside and galacto-oligosaccharides (GOS)
from lactose was able to generate products which positively modulated the
microbiome with a sweetness profile similar to sugar. The products sweetness,
bulking and prebiotic fibre properties could make it a suitable replacement to
sugar in everyday products.  This is one of a number of SweetBiotix®
products developed for different application types in food, beverages, and
dairy.  Publications by independent authors in peer reviewed journals are
critical in establishing industry awareness and credibility in the Company's
products and provide valuable marketing assets to support product launches.

 

5.    New Product Development-Extruded Puffs: The Company has been
developing low calorie, high prebiotic fibre puffs that make you feel full for
longer and reduce your food cravings as an extension of its SlimBiome® and
LeanBiome® ranges. Taste testing of four flavours has been successful and
investors should start seeing these products launched online and with partners
later this year. This is all part of an ongoing product development programme
with partners to extend the range of products containing SlimBiome® and
LeanBiome®.

 

My Protein Breakfast Smoothie: The Company was pleased to see the recent
launch of a breakfast smoothie range containing LeanBiome® by The Hut Group
as part of its MYProtein range.

 

Stephen O'Hara, CEO of OptiBiotix Health plc commented: "The Company has been
working to develop new first-generation products like LeanBiome® and
WellBiome® into the sports nutrition and health and wellbeing market
respectively, extend its product range for SlimBiome®, and provide scientific
publications to support partners launching second generation products like
SweetBiotix® and our microbiome modulators. This is all part of a process of
gradually increasing the range of products, applications, and territories
creating the potential to open larger market opportunities putting the Company
in a strong position for future growth in this exciting area of healthcare."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                    Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEALXNFSLAEFA